Minerva Neurosciences, Inc. (NERV) stock surged +2.33%, trading at $2.64 on NASDAQ, up from the previous close of $2.58. The stock opened at $2.61, fluctuating between $2.61 and $2.67 in the recent session.
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Employees | 9 |
Beta | 0.132 |
Sales or Revenue | $0.00 |
5Y Sales Change% | 0% |
Fiscal Year Ends | December |
Sector | Healthcare |
Industry | Biotechnology |
Minerva Neurosciences, Inc. (NASDAQ: NERV) stock price is $2.64 in the last trading session. During the trading session, NERV stock reached the peak price of $2.67 while $2.61 was the lowest point it dropped to. The percentage change in NERV stock occurred in the recent session was 2.33% while the dollar amount for the price change in NERV stock was $0.06.
The NASDAQ listed NERV is part of Biotechnology industry that operates in the broader Healthcare sector. Minerva Neurosciences, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Remy Luthringer Ph.D.
Executive Chairman & Chief Executive Officer
Mr. Geoffrey Robin Race F.C.M.A., FCMA, M.B.A., MBA
Pres
Mr. Frederick W. Ahlholm CPA, CPA
Senior Vice President, Chief Financial Officer & Sec.
Mr. Joseph Reilly
Senior Vice President & Chief Operating Officer
Mr. William B. Boni
Vice President of Investor Relations & Corporation Communications
Prof. Michael Davidson M.D.
Chief Medical Officer
Dr. Ramana Kuchibhatla Ph.D.
Senior Vice President and Head of R&D
NERV's closing price is 14.16% higher than its 52-week low of $2.26 where as its distance from 52-week high of $13.49 is -80.88%.
Number of NERV employees currently stands at 9.
Official Website of NERV is: https://www.minervaneurosciences.com
NERV could be contacted at phone 617 600 7373 and can also be accessed through its website. NERV operates from 1601 Trapelo Road, Waltham, MA 02451, United States.
NERV stock volume for the day was 2.93K shares. The average number of NERV shares traded daily for last 3 months was 15.5K.
The market value of NERV currently stands at $18.46M with its latest stock price at $2.64 and 6.99M of its shares outstanding.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com